News
Zur Aufbesserung seiner Finanzen ist der angeschlagene Hongkonger Bauprojektentwickler New World Development dem Vernehmen ...
Die Trump Media & Technology Group — die hinter der Social-Media-Plattform Truth Social steht — hat beschlossen, Aktien im ...
Ibrahim Aldoss, MD, discusses a post hoc analysis of ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who did not achieve early MRD negativity.
2d
GlobalData on MSNSAGA Diagnostics launches multi-cancer MRD platform in USSAGA Diagnostics has commercially launched its Pathlight test in the US to detect residual disease and recurrence. Comprising ...
Myriad Genetics, Inc. (MYGN) Showcases Breakthrough MRD Data and AI-Driven Cancer Tools at ASCO 2025
Myriad Genetics, Inc. (NASDAQ:MYGN) is making waves at the 2025 ASCO Annual Meeting, presenting seven new research studies ...
1d
Bizcommunity on MSNMinerals Council South Africa inputs not reflected in MRD BillThe Mineral Resources Development Bill (MRD) does not reflect inputs from the Minerals Council South Africa. The Mineral ...
A new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data presented at the annual meeting of the American Society of Clinical ...
4h
WKRG on MSNParts of Mobile Bay reopened for harvesting oystersAs of May 29, areas of Mobile Bay are open to harvesting oysters again, according to the Alabama Department of Health.
2d
MedPage Today on MSNNew Blood Test for HPV+ Head and Neck Cancer Tops Existing Tests, Tissue BiopsyBased on whole-genome sequencing (WGS), the investigational test detected circulating tumor (ct)DNA with a sensitivity and ...
22h
News-Medical.Net on MSNNew four drug combination sets new standard in myeloma careA new four-drug combination is highly effective and safe in patients with newly diagnosed multiple myeloma, according to data ...
Explore Allogene's innovative CAR-T therapies targeting cancer & autoimmune diseases. ASCO updates on ALLO-316 could validate ...
A zanubrutinib, venetoclax, and obinutuzumab triplet achieved deep remissions and high undetectable measurable residual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results